Microdosing — taking psychedelic substances at doses too small to produce noticeable acute effects — became a topic of widespread discussion in the late 2010s. Anecdotal reports proliferated, often describing improvements in mood, focus, creativity, and overall wellbeing. The practice was widely covered in popular media before serious research had been conducted.
In the years since, controlled studies have started to catch up with the anecdotes. The picture they paint is more nuanced than either the enthusiastic or dismissive accounts would suggest. This article reviews what those studies have shown.
Defining Microdosing
A microdose, broadly, is a sub-perceptual dose of a psychedelic — small enough that the person taking it does not notice acute drug effects. For psilocybin, this typically falls in the range of roughly 0.1 to 0.3 grams of dried mushroom material, or approximately 1 to 3 milligrams of pure psilocybin. The exact threshold varies between individuals.
Most popular microdosing protocols involve dosing on an intermittent schedule. The two most commonly cited are the Fadiman protocol (one dose every three days) and the Stamets protocol (four days on, three days off, often with added niacin and lion’s mane mushroom). The frequency is intended to avoid tolerance buildup, which develops rapidly with classic psychedelics.
The Naturalistic Studies
Early research on microdosing took the form of large naturalistic surveys — recruiting people who were already microdosing and assessing their experiences with validated psychological scales. Studies of this type, including work led by Vince Polito and Harriet de Wit, generally reported improvements in self-rated wellbeing, mood, and certain cognitive measures over weeks of microdosing.
The naturalistic design has clear limitations. Self-selected participants may differ from the general population in ways that affect outcomes. Expectancy effects — improvements caused by the belief that the substance is working — cannot be separated from pharmacological effects. The dose, source, and purity of the substance vary.
Still, the surveys established something important: a substantial number of people were microdosing, often consistently over months, and reporting benefits. Whether the reported benefits were due to the substance, the expectation, or both was a question that controlled studies needed to address.
The Placebo-Controlled Trials
A series of placebo-controlled trials in 2020-2024 attempted to isolate the pharmacological contribution. These trials randomized participants to receive either active psilocybin doses or placebo on a microdosing schedule, with both researchers and participants blinded to which they were receiving.
The headline finding from most of these studies has been consistent and somewhat humbling: when controlled for placebo, the differences between active microdosing and placebo on most outcomes have been small or non-existent.
A particularly elegant 2021 study by Balázs Szigeti and colleagues used a “self-blinding” design where participants prepared their own capsules — some active, some placebo — and tracked their experiences without knowing which was which. Both groups reported substantial improvements in wellbeing measures. The active group did not significantly outperform the placebo group on most outcomes.
This does not mean microdosing has no effects. It means that the bulk of the subjective improvement many people experience appears to come from the structured attention to wellbeing — the act of taking something and observing oneself — rather than from the pharmacological action of the substance.
Where Active Effects Have Been Detected
Some controlled studies have found differences between active microdosing and placebo, but these tend to be on specific cognitive or perceptual measures rather than on broad wellbeing.
Time perception, for instance, appears to be modestly altered at microdose levels. Some studies have found small changes in pain perception thresholds. A handful have reported subtle differences in convergent vs. divergent thinking on creativity tasks, though these findings have not always replicated.
The pattern that emerges is one where pharmacological effects at microdose levels are real but modest, and where they affect specific narrow measures rather than the broad domains — mood, productivity, creativity, focus — that the popular narrative emphasizes.
Risks and Practical Considerations
Microdosing is generally well-tolerated in the studies conducted to date. Adverse events have been mild and infrequent. The chronic safety profile of long-term microdosing remains poorly characterized — most studies have lasted weeks rather than months or years — and there are theoretical concerns about cardiac valvulopathy from chronic 5-HT2B receptor stimulation that have not been adequately ruled out.
The practical issue most commonly reported by people who try microdosing is dose precision. Mushrooms vary substantially in potency between specimens and between species, and accurate dosing without laboratory testing is difficult. People who attempt to microdose often unintentionally take a higher dose than intended.
What to Make of This
The evidence on microdosing supports a cautious interpretation. The practice appears safe in the short term. It produces modest and inconsistent effects beyond placebo on broad psychological measures. Some specific cognitive and perceptual effects appear to be real. The reported benefits from naturalistic use are partly pharmacological and largely not.
This is not a case where the popular narrative is entirely wrong, but it is a case where the popular narrative substantially overstates the reliability and magnitude of effects. Anyone considering microdosing should understand that the most likely outcome — based on the controlled evidence — is something that closely resembles a structured wellness practice with some pharmacological assistance, rather than a transformative cognitive enhancement.
The research is still developing. Larger and longer studies may detect effects that current designs have missed. For now, the evidence is what it is, and it supports neither dismissal nor enthusiasm.